Biohaven Ltd. Investors: Please contact the Portnoy Law Firm to recover your losses.

Core Viewpoint - Biohaven Ltd. is facing a class action lawsuit due to alleged false and misleading statements regarding its drug candidates, leading to significant stock price declines during the class period from March 24, 2023, to May 14, 2025 [1][4]. Company Overview - Biohaven is a biopharmaceutical company focused on therapies in immunology, neuroscience, and oncology, with key product candidates including troriluzole for spinocerebellar ataxia and BHV-7000 for bipolar disorder [3]. Allegations and Impact - The class action lawsuit claims that Biohaven overstated the regulatory prospects of troriluzole and the efficacy of BHV-7000, which misled investors and resulted in substantial financial losses [4][6]. - Specific disclosures that negatively impacted Biohaven's stock price include: - On July 27, 2023, the FDA refused to review the NDA for troriluzole, causing a nearly 23% drop in stock price [6]. - On March 3, 2025, disappointing clinical trial results for BHV-7000 led to a nearly 14% decline [6]. - On April 25, 2025, the withdrawal of the Marketing Authorization Application for troriluzole in Europe resulted in over a 15% drop [6]. - On May 14, 2025, the FDA extended the PDUFA date for the troriluzole NDA, causing a more than 19% decline in stock price [6].